spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

14th World Advanced Therapies & Regenerative Medicine Congress 2018

World_Advanced_Therapies_and_Regenerative_Medicine_Congress_2018

16-18 May 2018
Business Design Centre, London, United Kingdom

In May 2018 the World Advanced Therapies & Regenerative Medicine Congress, will bring together 800+ attendees and explore the rapidly developing world of ATMPs (Advanced Therapy Medicinal Products). From clinical translation to commercialisation this congress will bring you the most exciting case studies and new data for stem cells, gene therapy, TCRs and gene editing. Experts in every area will help you tackle the process and regulatory hurdles of developing all new therapeutic formats all the way through manufacture and into the clinic.

The event will take place alongside the co-located World Precision Medicine Congress, hosting300+ speakers, 10 tracks of content across the 3 days, enabling networking opportunities with 800+ leading industry professionals.

For a 15% discount on your conference ticket, quote code ‘HMFQ’ at the online checkout

Confirmed speakers include:

•                   Susan Solomon, CEO and Co-Founder, New York Stem Cell Foundation

•                   Sven Kili, Vice President & Head, Gene Therapy Development, GSK

•                   Eric Soller, Vice President of Corporate Development & Strategy, BlueRock Therapeutics

•                   Margo Roberts, CSO, Kite Pharma

•                   Sue Hill, Chief Scientific Officer, NHS

•                   Brad Perkins, Chief Medical Officer, Human Longevity

•                   Julia Wilson, Associate Director, Wellcome Trust Sanger Institute

•                   Paul P. Tak, Academic Medical Centre, University of Amsterdam;  Senior Vice President of Research & Development Pipeline, Chief Immunology Officer, GSK

•                   Elizabeth Shpall, Director, MD Anderson Cancer Center

•                   Joanne Kurtzberg, Director, Carolinas Cord Blood Bank, Duke University

•                   Todd McAllister, Executive Director, Amnion Foundation

•                   Colleen Delaney, Founder and Chief Medical Officer, Nohla Therapeutics

•                   Ajan Reginald, Chief Executive Officer, Celixir

•                   Alain Vertθs, Managing Director, NxR Biotechnologies

•                   Andrι Choulika, Chairman & Chief Executive Officer, Cellectis

•                   Benjamin Shepherd, Director, Therapeutics, Organovo

•                   Eduardo Bravo, Managing Director and CEO, TiGenix

•                   Giuseppe Mazza, Chief Executive & Scientific Officer, Engitix

•                   James Miskin, Chief Technical Officer, Oxford BioMedica

•                   Jane Lebkowski, ‎President of R&D, Asterias Biotherapeutics

•                   Jeff Abbey, CEO, Argos Therapeutics

•                   John Tchelingerian, CEO, Promethera, Biosciences

•                   Katy Spink, Chief Operating Officer, Asterias Biotherapeutics

•                   Kristin Comella, Chief Science Officer, US Stem Cell Inc

•                   Michael Stein, Chairman & CEO, Oxstem

•                   Michael West, CEO, BioTime; CEO , AgeX Therapeutics

•                   Nick Crabb, Programme Director – Scientific Affairs, NICE

•                   Todd McAllister, Executive Director, Amnion Foundation

•                   Yen Choo, CEO, Progenitor Therapeutics

•                   Zami Aberman, Chairman & CEO, Pluristem Therapeutics

Key topics include:

•                   The next generation of ATMPs

•                   Regulation, reimbursement & commercialisation for advanced therapies around the globe

•                   CRISPR & gene editing

•                   Stem cells as a tool for drug discovery

•                   What’s next for cell and gene therapy, new era of regenerative medicine?

•                   New paradigms in manufacture: gene therapy & viral vectors

•                   Clinical development of immunotherapy & cell therapy

•                   New frontiers in repair and replacement of diseased tissues & organs

•                   Product, process & manufacturing development of ATMPS

For a 15% discount on your conference ticket, quote code ‘HMFQ’ at the online checkout

phone +44 (0)20 7092 1000
email enquiry.uk@terrapinn.com
web https://goo.gl/99eSQP
email Business Design Centre, London
 
Print this page
Send to a friend
   
spacer
Industry Events

Vaccine Manufacturing

23-25 April 2018, RAI, Amsterdam

Changing the shape of vaccine development, manufacturing and delivery.
More info >>

Banner of ChinaBio_Events_102 on Samedan
White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>


News and Press Releases

PCI’s Tredegar Site Announces Significant Expansion of Analytical Laboratories at its Center of Excellence for Contained Manufacturing

Philadelphia, USA- March 19, 2018. Global pharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to announce a laboratory expansion at its site in Tredegar, Wales, UK. 
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement